Dong Fangying, Zhou Jing, Wu Yijie, Gao Zhaofeng, Li Weiwei, Song Zhengwei
Emergency Department, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Department of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Front Cell Dev Biol. 2025 Jan 15;12:1499111. doi: 10.3389/fcell.2024.1499111. eCollection 2024.
Pancreatic cancer (PC) remains one of the most lethal malignancies, primarily due to its intrinsic resistance to conventional therapies. MicroRNAs (miRNAs), key regulators of gene expression, have been identified as crucial modulators of drug resistance mechanisms in this cancer type. This review synthesizes recent advancements in our understanding of how miRNAs influence treatment efficacy in PC. We have thoroughly summarized and discussed the complex role of miRNA in mediating drug resistance in PC treatment. By highlighting specific miRNAs that are implicated in drug resistance pathways, we provide insights into their functional mechanisms and interactions with key molecular targets. We also explore the potential of miRNA-based strategies as novel therapeutic approaches and diagnostic tools to overcome resistance and improve patient outcomes. Despite promising developments, challenges such as specificity, stability, and effective delivery of miRNA-based therapeutics remain. This review aims to offer a critical perspective on current research and propose future directions for leveraging miRNA-based interventions in the fight against PC.
胰腺癌(PC)仍然是最致命的恶性肿瘤之一,主要是由于其对传统疗法具有内在抗性。微小RNA(miRNA)作为基因表达的关键调节因子,已被确定为这种癌症类型中耐药机制的关键调节因子。本综述综合了我们对miRNA如何影响胰腺癌治疗效果的最新认识进展。我们全面总结并讨论了miRNA在介导胰腺癌治疗耐药性中的复杂作用。通过强调与耐药途径相关的特定miRNA,我们深入了解了它们的功能机制以及与关键分子靶点的相互作用。我们还探讨了基于miRNA的策略作为克服耐药性和改善患者预后的新型治疗方法和诊断工具的潜力。尽管有前景良好的进展,但基于miRNA的治疗方法的特异性、稳定性和有效递送等挑战仍然存在。本综述旨在对当前研究提供批判性观点,并为在抗击胰腺癌中利用基于miRNA的干预措施提出未来方向。
Front Cell Dev Biol. 2025-1-15
Int J Mol Sci. 2023-12-15
Ann Med Surg (Lond). 2024-4-22
Front Mol Biosci. 2024-9-3
J Pancreatol. 2019-12
J Cell Mol Med. 2013-9-23
J Hematol Oncol. 2024-6-4
Int J Mol Sci. 2024-3-31
Cancer Biol Ther. 2023-12-31